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Abstract
Background: SPARC (secreted protein, acidic and rich in cysteine) is closely related with the progress, invasion and 
metastasis of malignant tumor and angiogenesis.
Methods: Using human colon adenocarcinoma tissues (hereinafter referred to as colon cancer) and their 
corresponding non-diseased colon from 114 patients' biopsies, the expression of SPARC and vascular endothelial 
growth factor (VEGF) were investigated by immunohistochemistry staining to assessment the relationship between 
SPARC and VEGF, as well as their prognostic significance in patients. Evaluation of VEGF expression level with the same 
tissues was used to establish the antigenic profiles, and the marker of CD34 staining was used as an indicator of 
microvessel density (MVD).
Results: SPARC expression was mainly in the stromal cells surrounding the colon cancer, and was significant difference 
in those tissues with the lymph node metastasis and differentiation degree of tumor. Expression of SPARC was 
significantly correlated with the expression of VEGF and MVD in colon cancer tissues. Patients with low or absence 
expressing SPARC had significantly worse overall survival and disease-free survival in a Single Factor Analysis; Cox 
Regression Analysis, SPARC emerged as an overall survival and disease-free survival independent prognostic factor for 
colon cancer.
Conclusion: The low expression or absence of stromal SPARC was an independent prognostic factor for poor 
prognosis of colon cancer. SPARC maybe involved in the regulation of anti-angiogenesis by which it may serve as a 
novel target for colon cancer treatment as well as a novel distinctive marker.
Background
Colon cancer is a common malignant tumor of digestive
tract. The incidence of colon cancer in China has
i n c r e a s e d  i n  r e c e n t  y e a r s .  A n g i o g e n e s i s  ( b l o o d  v e s s e l
growth) is a creitical process for tumor growth, invasion
and metastasis. VEGF expression was closely related with
biological behavior of colon cancer and significantly asso-
ciated with high intratumoral microvessel density
(MVD), and its over-expression in colon cancer tissue
indicated poor prognosis [1]. Therefore, VEGF receptor
inhibitors have been used to prevent the formation of
blood vessels by arresting the growth of tumor cells. As a
vascular endothelial marker, CD34 antigen by immuno-
histochemistry is used to evaluate the microvessel density
(MVD) by reflecting the numbers of microvessel forma-
tion in the tumor tissues directly.
SPARC (Secreted Protein, Acidic and Rich in Cysteine;
also known as BM-40 and osteonectin) was initially iden-
tified as osteonectin by Termine et al [2] as a bone-spe-
cific phosphoprotein that binds to collagen fibrils and
hydroxyapatite at distinct sites. Recently, SPARC has gen-
erated considerable interests as a multi-faceted protein
that belongs to a family of matricellular proteins. Differ-
ential expression of SPARC has been observed in various
human cancers, and it is unclear why it has variable
effects on tumor growth in different tissues [3]. For exam-
p l e ,  h i g h e r  l e v e l s  o f  S P A R C  e x p r e s s i o n  h a v e  b e e n
reported in breast cancer, melanoma and glioblastomas.
Y e t ,  l o w e r  l e v e l s  o f  S P A R C  e x p r e s s i o n  h a v e  a l s o  b e e n
found in other types of cancers, such as ovarian and pan-
creatic. This pattern of decreased SPARC levels would
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suggest an inhibitory role for SPARC in tumor formation.
In animal models of ovarian cancer [4,5], the absence of
SPARC could de-repress the expressions of VEGF, by
which to promote the angiogenic and metastatic poten-
tial of tumors. Other studies also found that, SPARC
could bind with VEGF and decrease the capability of
VEGF binding with its receptor, and resulted in the inhi-
bition of endothelial cell proliferation [6-8].
The purpose of this study, was to explore the expression
of SPARC and its relationship with angiogenesis, as well
as the relationship between the other clinicopathological
factors and prognosis with the expression of SPARC and
VEGF. The results obtained in the current study were
expected to provide an evidence for a novel molecular
target therapy in colon cancer.
Materials and methods
Patients and tissue specimens
One hundred and fifty-three of colon cancers obtained
between August 1999 and December 2003 were identified
from our pathology files in Department of Pathology at
the First Clinical Hospital of Shanxi Medical University,
China. After review, 39 cases with synchronous other
malignant tumors, familial adenomatous polyposis, coli-
tis ulcerosa or Crohn's disease, using neoadjuvant ther-
apy, lack of confirmatory surgical material, and/or clinical
follow-up were excluded from this study. The remaining
114 cases were selected for SPARC, VEGF and CD34
staining.
A pair of tissue samples for each case was collected
from the tumor tissues and their corresponding non-dis-
eased colon. The protocol of this study was approved by
our Institutional Review Board before all specimens were
examined by the experienced pathologists. Histological
examination was carried out on paraffin-embedded sec-
tions stained with hematoxylin & eosin (H&E). The
patients were followed-up in a range of 4-110 months
(median = 53 months), the mean survival time was 99.0
months and the five-year survival rate was 76.0%, median
survival time was 81.7 months. Seventy two of these
patients were found to be recurrence or metastasis with
the metastatic sites of lymph nodes, stomach, spleen,
liver, pancreas, ovary, cervix and bladder, and forty two
cases died during the follow-up period. Other clinical and
pathologic parameters were obtained from the pathologi-
cal reports, including tumor differentiation, lymphocytic
infiltration in the tumor interstitial and the TNM stage,
and all of these data were reviewed and confirmed by the
pathologists in our department (Table 1).
Using WHO-OMS, IARC classification standard for
colon cancer: well-differentiated adencarcinoma, > 95%
glandular structure in tumor; moderately differentiated
adencarcinoma, 50%~95% glandular structure in tumor;
poorly differentiated adencarcinoma, 5%~50% glandular
structure in tumor; anaplastic carcinoma < 5% glandular
structure in tumor.
Immunohistochemical (IHC) staining and scoring
Sections (4 μm) from the paraffin-embedded, formalin-
fixed archival colon tissues were fixed on the charged
slides for immunohistochemical analysis using non-bio-
tin detection system (EnVision, Anti-Mouse/Rabbit-HRP,
DAKO). Primary mouse monoclonal antibodies to
SPARC (clone PP16, dilution 1:100), VEGF (clone C-1,
dilution, 1:100) and CD34 (clone 43A1, dilution 1:150)
(Santa Cruz, California, USA) were used in the study. All
slides were deparaffinized with xylene and rehydrated
through graded ethanol ending with distilled water. Then
endogenous peroxidase was blocked by 3% hydrogen per-
oxide for 15 minutes. Sections for SPARC, VEGF and
CD34 for immunohistochemical were subjected to
microwave antigen retrieval with 0.1M citrate buffer (pH
6.0) at 98°C for 10 minutes, then were incubated over-
night at 4°C in a humidified chamber, followed by EnVi-
sion detection incubated for 30 minutes at room
temperature (RT). The staining were visualized by incu-
bating with 3,3'-diaminobenzidine for 5 minutes at RT,
then counterstained with hema to xylin. Negative ( omis-
sion of primary antibody) and positive controls (paraffin
sections of clone cancer) were run in parallel.
The intensity of immunostaining for SPARC was
reviewed and scored according to the location of cyto-
plasmic with or without positive nucleus and results are
presented by two independent observers without knowl-
edge of the clinicopathological outcomes of the patients.
The proportion of cells with SPARC expression was rated
as follows [9-11]: 1 point, < 5% positive tumor cells; 2
points, 5~25% positive cells; 3 points, 26~75% positive
cells; and 4 points, > 75% positive cells, and the intensity
of staining varied from weak to strong. The intensity was
classified as a scale of 0 (no staining), 1 (weak staining,
light yellow), 2 (moderate staining, yellowish brown), and
3 (strong staining, brown). The specimens were attrib-
uted to four groups, according to their overall score:
Absent expression, when < 5% of cells stained positive,
regardless of intensity; weak expression, a total of 3
points; moderate expression, 4-5 points; and strong
expression, 6-7 points. For statistical purpose, tumor cells
were then scored according to a two-scale system: tumors
with absent or weak expression was low reactivity, and
with moderate to strong expression was high reactivity.
The assessment of association of SPARC with other
parameters using SPARC is either evaluated with a cate-
gorical variable (low reactivity vs. high reactivity) or a
continuous variable (the percentage of SPARC-positive
cells within a sample).
The staining results of VEGF were scored according to
the percentage of cytoplasmic and/or membrane specificLiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:71
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positive tumor cells. VEGF staining was reported as four
grades, "-", positive staining in less than 5% of tumor cells;
"1+" between 5% and 25%; "2+", between 26% and 50%;
and "3+", more than 50%. The grades with less than 2+
were considered as low reactivity for VEGF, otherwise as
high reactivity.
Evaluation of microvessel density
Microvessels were identified by immunostaining
endothelial cells with the mouse anti-human monoclonal
antibody CD34. Microvessel density (MVD) was assessed
according to the international consensus [12]. The entire
section was scanned systematically at low magnification
(× 100) in order to identify the most intense areas of neo-
vascularization ("hotspots") within the tumor. After five
hotspots areas with the highest number of capillaries and
small venules were identified, microvessels were counted
at high power magnification (× 400), and the average of
count in five fields was calculated. MVD was quoted as a
continuous variable [13,14].
Statistical analysis
The Chi-square test or Fisher's exact probability test for
proportion was used to analyze the relationship between
SPARC and VEGF expression, and clinicopathologic
characteristics. One-way ANOVA test and Linear regres-
sion analysis was used to assess the correlations among
the continuous variables. Spearman rank correlation
coefficient test analysis was performed to examine the
correlations among different variables.. Survival curves
were plotted by the Kaplan-Meier method, and compared
by the log-rank test. To identify independent prognostic
factors, including cancer recurrence, distant metastasis
or death from disease, the Cox regression analysis was
performed with the endpoints for disease-free survival
(DFS) and overall survival (OS), respectively. A P-value of
Table 1: Clinicopathologic characteristics of the colon cancer patients
Parameters No. of patients(%) Parameters No. of patients(%)
Age (median, 59 years) N2 13(11.4)
< 59 48(42.1) Recurrence/distant metastasis
≥ 59 66(57.9) Yes 23(20.0)
Gender No 91(79.8)
Men 54(47.4) L/infiltrationa
Women 60(52.6) Yes 41(36.0)
Tumor size(average 5.0) No 73(64.0)
< 5.0 52 (45.6) depth of invasion
≥ 5.0 62(54.4) T2 15(13.2)
Localization T3 88(77.2)
colon ascendens 27(23.7) T4 11 (9.6)
flexura hepatica 22(19.3) Distant metastasis
colon transversum 6(5.3) M0 102(89.5)
flexura lienalis 8(7.0) M1 12 (10.5)
colon descendens 6(5.3) TNM staging
colon sigmoideum 45 (39.5) I 11(9.6)
Tumor differentiation II 47(41.2)
low 16(14.0) III 44(38.6)
moderate 68(59.6) IV 12(10.5)
high 30(26.3) Clinical outcome
Lymph node metastasis Disease free 72(63.2)
N0 65(57.0) Metastasis or recurrence 72(63.2)
N1 36(31.6) Death 42(36.8)
a lymphocytic infiltration in the tumor interstitialLiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:71
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less than 0.05 was considered statistically significance.
SPSS 11.5 was used for the statistical analysis.
Results
Expression of SPARC, VEGF, and CD34 in colon cancer and 
normal colon mucosa tissue
Expression of SPARC protein was determined by immu-
nohistochemistry staining in 114 cases of paraffin-
embedded colon cancer tissues and their corresponding
non-diseased colon tissue. SPARC was mainly localized
in the cytoplasm and was detected in the normal colonic
epithelial cells (Fig 1a), the colon cancer cells and the
mesenchymal and stromal cells (MSC) of colon cancer
(Fig 1b). In this study, the degree of the expression of
SPARC showed that 81 cases (71.1%) with low reactivity
and 33 cases (28.9%) with high reactivity in tumor cells,
61 cases (53.5%) with low reactivity and 53 cases (46.5%)
with high reactivity in the MSC surrounding the tumor,
and 84 cases (73.7%) with low reactivity and 30 cases
(26.3%) with high reactivity in the normal colon mucosa
tissue, respectively. SPARC expression was no significant
difference between the reactivity in tumor cells and in
their corresponding non-diseased colon mucosa (P  >
0.05), but was statistically significant difference between
that in MSC and in tumor cells (P < 0.05), and between
t h a t  i n  M S C  a n d  n o r m a l  m u c o s a  i n  c o l o n  t i s s u e  ( P  <
0.05), respectively.
The rate of positive VEGF expression was 72.8% in
colon cancer cells and 47.4% in normal mucosal epitheli-
cal cells (Fig 1c, d) respectively, with a significant differ-
ence between them (P < 0.05).
CD34 was used to mark vascular endothelial cell or
endothelial cell clustering around the tumors for MVD.
The mean value of MVD was 11.60 ± 5.68 in all cases of
the colon cancer, and MVD in tumor cells nest was signif-
icantly higher than that in the surrounding normal tissue
(P < 0.05, Fig 1e, f).
SPARC and VEGF protein expression vs. the MVD and the 
clinicopathological parameters
SPARC expression in colon cancer cells was no significant
difference determined with clinicopathological parame-
ters (P > 0.05), but SPARC expression in MSC was (1) sig-
nificantly negative related to the differentiation of tumor
(P < 0.05, r = -0.175); (2) statistically significant difference
with lymph node metastasis (P < 0.05); and (3) no signifi-
cant difference with the patients age, sex, tumor size,
tumor location, lymphatic infiltration, and TNM staging
(P > 0.05) (Table 2).
VEGF expression was statistically significant difference
with lymph node metastasis, and was significantly corre-
lated with TNM staging (P < 0.05, r = 0.302) (Table 3).
The average MVD around the tumor nest had no signifi-
cant difference with clinical pathological parameters (P >
0.05) (Table 3).
Figure 1 Expression of SPARC, VEGF and CD34 in colon cancer and normal colon mucosa by Immunohistochemical staining. a, c and e. 
SPARC, VEGF and CD34 expression in normal colon mucosa away from the colon cancer tissues; b. SPARC expression in MSC of colon cancer; d and f. 
VEGF and CD34 expression in colon cancer.
 
 
 
 
 
 
 
 
 
 
 
 
a c  e 
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Table 2: Relationship of SPARC expression in colon cancer tissues with clinicopathological parameters
Tumors cell MSC
Parameters low reactivity high reactivity P value low reactivity high reactivity P value
n%n% n%n%
Agea 0.379 0.904
< 59 48 32 66.7 16 33.3 26 54.2 22 45.8
≥ 59 66 49 74.2 17 25.8 35 53.0 31 47.0
Gender 0.276 0.276
men 54 41 75.9 13 24.1 26 48.1 28 51.9
women 60 40 66.7 20 33.3 35 58.3 25 41.7
Tumor sizeb 0.222 0.658
< 5.0 52 34 65.4 18 34.6 29 55.8 23 44.2
≥ 5.0 62 47 75.8 15 24.2 32 51.6 30 48.4
Localization 0.140 0.926
colon ascendens 27 22 81.5 5 18.5 14 51.9 13 48.1
flexura hepatica 22 17 77.3 5 22.7 12 54.5 10 45.5
colon transversum 6 6 100 0 0 3 50.0 3 50.0
flexura lienalis 8 6 75.0 2 25.0 3 37.5 5 62.5
colon descendens 6 3 50.0 3 50.0 4 66.7 2 33.3
colon sigmoideum 45 27 60.0 18 40.0 25 55.6 20 44.4
Tumor differentiation 0.930 0.046
low 16 12 75.0 4 25.0 4 25.0 12 75.0
moderate 68 48 70.6 20 29.1 39 57.4 29 42.6
high 30 21 70.0 9 30.0 18 60.0 12 40.0
Lymph node metastasis 0.462 0.013
N0 65 44 67.7 21 32.3 28 43.1 37 56.9
N1 36 26 72.2 10 27.8 22 61.1 14 38.9
N2 13 11 84.6 2 15.4 11 84.6 2 15.4
R/DMc 0.490 0.746
Yes 23 15 65.2 8 34.8 13 56.5 10 43.5
No 91 66 72.5 25 27.5 48 52.7 43 47.3
L/infiltrationd 0.626 0.678
Yes 41 28 68.3 13 21.7 23 56.1 18 43.9
No 73 53 72.6 20 27.4 38 52.1 35 47.9
depth of invasion 0.459 0.850
T2 15 12 80.0 3 20.0 8 53.3 7 46.7
T3 88 60 68.2 28 31.8 48 54.5 40 45.5
T4 11 9 81.8 2 18.2 5 45.5 6 54.5
Distant metastasis 0.504 0.797
M0 102 71 69.6 31 30.4 55 53.9 47 46.1
M1 12 10 83.3 2 16.7 6 50.0 6 50.0
TNM staging 0.431 0.297
I 11 9 81.8 2 22.2 5 45.5 6 54.5
II 47 30 63.8 17 36.2 21 44.7 26 55.3
III 44 32 72.7 12 27.3 28 63.6 16 36.4
IV 12 10 83.3 2 16.7 7 58.3 5 41.7
a median, 59 years; b mean, 5.0 cm; c R/DM-Recurrence/distant metastasis;
d lymphocytic infiltration in the tumor interstitialLiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:71
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Correlation analysis of SPARC expression in MSC with VEGF 
expression and MVD
Using Spearman rank correlation analysis, SPARC
expression in MSC was negative significantly related with
VEGF in colon cancer tissue (P < 0.05, r = -0.208) (Table
3, Fig 2). Linear regression analysis of SPARC-positive
percentage of individual cases in MSC showed significant
correlation with MVD in these human colon cancer spec-
imens (P < 0.05, r = -0.578) (Table 3, Fig 3).
Survival analysis
Kaplan-Meier analysis and the log-rank test were used to
evaluate the effects of the SPARC and VEGF expression
on survival. There was a significantly unexpected influ-
ence on SPARC expression in MSC between the group of
low reactivity and high reactivity on both OS (P < 0.05)
and DFS (P < 0.05) of the patients (Fig 4a, b). On the con-
trary, patients with high reactivity of VEGF have poor
prognosis than those with low reactivity for either the
overall survival (P < 0.05) or disease-free survival (P <
0.05) (Fig 4c, d).
In this study, the multivariate survival analysis were
used, including SPARC expression level in MSC, VEGF
Figure 2 Correlation analysis of SPARC expression in MSC and 
VEGF expression in colon cancer.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Relationship of VEGF expression and MVD with clinicopathologic parameters and SPARC expression
Parameters VEGF P value MVD (CD34) P value
(-) (1+) (2+) (3+) (mean ± S.D.) (ANOVA)
Total 114 31 27 22 34 11.60 ± 5.68
Age 0.612 0.319
< 59 48 11 10 10 17 12.23 ± 6.19
≥ 59 66 20 17 12 17 11.15 ± 5.28
Tumor differentiation 0.112 0.952
low 16 6 2 3 5 11.24 ± 7.30
moderate 68 16 18 9 25 11.72 ± 5.30
high 30 9 7 10 4 11.53 ± 5.75
Lymph node metastasis 0.001 0.879
N0 65 23 20 13 9 11.80 ± 5.54
N1 36 7 6 7 16 11.20 ± 6.74
N2 13 1 1 2 9 11.74 ± 2.59
depth of invasion 0.601 0.281
T2 15 5 3 4 3 11.28 ± 5.63
T3 88 24 21 14 29 11.33 ± 5.66
T4 11 2 3 4 2 14.20 ± 5.72
TNM staging 0.002 0.295
I 11 4 3 3 1 12.00 ± 6.00
II 47 17 15 8 7 10.99 ± 4.70
III 44 8 6 6 24 11.04 ± 6.26
IV 12 2 3 5 2 14.26 ± 5.46
SPARC in MSC 0.0001 0.027
low reactivity 61 17 6 13 25 12.69 ± 5.71
high reactivity 53 14 21 9 9 10.34 ± 5.43Liang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:71
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expression level, MVD, tumor differentiation, lymph
node metastasis, lymphoid infiltration, invasion depth,
distant metastasis and TNM staging to test the indepen-
dent effects of SPARC on survival (Table 4). The results
indicated that SPARC expression (P  < 0.05), VEGF
expression (P < 0.05) and TNM staging (P < 0.05) were
independent prognostic factors for OS, and SPARC
expression (Table 5) was also an independent prognostic
factor of DFS (P < 0.05).
Discussion
The development, invasion and metastasis of malignant
tumors depend on a pathological environment which
provides sufficient nutrients to promote the neovascular-
ization and complex cell-cell and cell-matrix interactions.
On the other hand, tumor cells can produce a number of
soluble proteins into the adjacent extracellular matrix
(ECM) organization to facilitate the communication
between tumor cells and their environment by stimulat-
ing the tumor cell growth.
SPARC as a member of the family of matricellular pro-
teins, is a calcium-binding protein. SPARC is not only
binding on the several resident proteins of the ECM, but
also is competitively binding on the cell membrane sur-
face growth factor receptor to modulate growth factor
signaling [2]. SPARC has profound influence on cancer
progression [15]. As a secreted acidic and cysteine-
enriched protein in the ECM, SPARC inhibits the prolif-
eration of different cell types and modulates tumor cell
aggressive features. This apparent paradox might result
either from the biochemical properties of the different
SPARC sources (endogenous or exogenous) or from dif-
ferential responses of malignant and stromal cells to
SPARC [16]. In cancer, the expression pattern of SPARC
is variable depending on the tumor types. For example, a
strong cytoplasmic SPARC expression was found in
stromal cells surrounding malignant tissues in breast can-
cer, but was absent in stromal cells of normal breast tis-
sues [17,18], and SPARC expression in the surrounding
stromal of breast cancer was significantly higher than
tumor cells [19,20]. Similar observations were made in
prostate cancer [21], bladder cancer [22], non-small cell
lung cancer [23] and ovarian cancer [24].
There are not only the differences in the pattern of
SPARC expression within tumors and the stroma sur-
rounding malignant tissues, but also the differential clini-
cal outcomes of SPARC expression in a variety of tumors.
Watkins, et al. [25] showed that high levels of SPARC
expression in tumor cells negatively correlated with the
overall survival of patients in breast cancer, but was unre-
lated to the disease-free survival. Recent studies have
shown that over-expression of SPARC in the surrounding
stromal of breast cancer was related with the better prog-
nosis of patients [19,20]. However, the increased SPARC
expression in prostate cancer, bladder cancer and non-
small cell lung cancer indicated a higher malignancy and
invasion of tumors with poor prognosis. In contrast, in
ovarian cancer, elevated SPARC expression inhibited the
invasion and metastasis of tumor cells [4].
Recently, the role of SPARC expression in colon cancer
was concerned greatly. To investigate if SPARC promotes
or inhibits the invasion and metastasis of tumor, the
expression level of SPARC in human colon cancer tissues
and their corresponding non-diseased colon by immuno-
histochemical method in the current study. The results in
our study showed that SPARC expression in MSC was
significantly higher than that in cancer cells and in nor-
mal mucosa tissues, and only SPARC expression in MSC
was significantly different with clinicopathological
parameters including tumor differentiation and lymph
node metastasis. Our results also showed that SPARC
expression was mainly in MSC and decreased in colon
cancer tissue, which indicated that SPARC might inhibit
the invasion and metastasis of tumor during colon cancer
development. Others considered that this suppression
might be related to the tumor growth, and SPARC had an
antiproliferative function through modulating cell cycle
regulatory proteins or growth factors [26]. Similar results
have been reported in lung cancer and pancreatic cancer
[27,28].
SPARC has been found to act as an angiogenesis inhibi-
tor by regulating the activities of growth factors like
VEGF and platelet-derived growth factor [29-32]. While
regulating VEGF, SPARC can bind to VEGF through EF-
arm of the FS and EC areas to inhibit VEGF-stimulated
proliferation of endothelial cells [7,8,33]. The role of
slowing and terminating the tumor growth with SPARC
by inhibiting the synthesis and secretion of VEGF has
Figure 3 Linear regression analysis of the percentage of SPARC 
stained in MSC with MVD.
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been reported in glioma [34]. Similarly , Chlenski et al.
[35] found that SPARC is an inhibitor of angiogenesis in
Schwann cells. They showed that MVD value of SPARC-
treating group was significantly lower than non-treated
control group and demonstrated that purified SPARC
potently inhibited neuroblastoma growth and angiogene-
sis in vivo.
In the current study, from the expression pattern of
SPARC and VEGF, we found that VEGF and SPARC were
mainly expressed in tumor cells and MSC, respectively.
The expression of the angiogenic factor VEGF and the
intratumoral vascular density were apparently not related
to the production of SPARC in MSC, however, high levels
of SPARC in MSC was significantly negative related with
VEGF expression and MVD counts. In addition, our
Figure 4 Kaplan-Meier survival curve for SPARC and VEGF protein expression in colon cancer patients. Comparison of overall as well as dis-
ease-free survival between the groups of patients with low and high SPARC and VEGF protein expression.
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results showed that VEGF was significantly different with
lymph node metastasis and TNM staging. VEGF expres-
sion was up-regulated in colon cancer along with the
decreased expression of SPARC. All of these results sug-
gest that SPARC may inhibit VEGF expression during the
process of new blood vessel growth by which indirectly
control the development, growth, invasion and metasta-
sis of tumor cells in colon cancer.
We also analyzed the relationships of SPARC and VEGF
expression with clinical prognosis in this study. The
results showed that patients with low expression of VEGF
were survival longer than those with high expression for
overall or disease-free survival evaluated by Kaplan-
Meier analysis. Similar results reported by Des et al. [1].
They investigated 27 kinds of VEGF expression in col-
orectal carcinoma using Meta analysis, and found that
high levels of VEGF expression were related with unfa-
vorable prognoses. Moreover, they revealed that VEGF
was a more effective marker than MVD for prediction of
overall survival in patients.
W e believe that increased expression of VEGF corre-
lates with decreased SPARC expression. Reduction of
SPARC may up-regulate the expression of VEGF, causing
the subsequent MVD increase in tumors and resulting in
a poor clinical outcome. Analysis for overall and disease-
free survival showed that patients with low or absence of
SPARC expression displayed a poor prognosis, when
compared with patients with higher SPARC expression.
Therefore, it may support an hypothesis that SPARC
potentially regulates the expression of angiogenesis factor
VEGF during colon cancer development, by regulating
Table 4: OS analysis of different prognostic factors in patients with colon cancer by Cox Regression Analysis
Parameters Regression
 Coefficient
Standard
 Error
Wald Relative
 Risk
95%CI P Value
lower upper
Tumor differentiation 0.076 0.280 0.074 1.079 0.623 1.869 0.785
Lymph node metastasis -0.174 0.363 0.230 0.840 0.412 1.712 0.632
L/infiltrationa -0.012 0.384 0.001 0.989 0.466 2.097 0.976
depth of invasion -0.344 0.431 0.639 0.709 0.305 1.649 0.424
Distant metastasis -0.205 0.459 0.200 0.815 0.331 2.003 0.655
TNM 0.959 0.363 6.972 2.609 1.280 5.316 0.008
SPARC 0.999 0.367 7.431 2.717 1.324 5.574 0.006
VEGF -0.311 0.153 4.136 0.733 0.543 0.989 0.042
MVD 0.026 0.028 0.887 1.027 0.972 1.085 0.346
a lymphocytic infiltration in the tumor interstitial
Table 5: DFS analysis of different prognostic factors in patients with colon cancer by Cox Regression Analysis
Parameters Regression
 Coefficient
Standard
 Error
Wald Relative
 Risk
95%CI P Value
lower upper
Tumor differentiation 0.157 0.355 0.196 1.170 0.583 2.348 0.658
Lymph node metastasis -0.165 0.622 0.070 0.848 0.250 2.873 0.792
L/infiltrationa -0.101 0.431 0.054 0.904 0.388 2.106 0.816
depth of invasion -1.021 0.611 2.792 0.360 0.109 1.193 0.095
TNM staging 0.881 0.565 2.433 2.413 0.798 7.298 0.119
SPARC 0.957 0.441 4.695 2.603 1.096 6.184 0.030
VEGF -0.242 0.192 1.598 0.785 0.539 1.143 0.206
MVD 0.039 0.031 1.607 1.040 0.979 1.104 0.205
a lymphocytic infiltration in the tumor interstitialLiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:71
http://www.jeccr.com/content/29/1/71
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indirectly the formation of blood capillary, to impact the
clinical prognosis of patients.
Clinicopathological parameters including lymph node
metastasis, lymphocytic infiltration in the tumor intersti-
tial, depth of invasion, distant metastasis, TNM staging,
may effect on the prognosis of patients, the expression of
SPARC and VEGF, and MVD value, with multivariable
models. The results of the analysis of the cinicopathologi-
cal parameters showed that SPARC expression influences
independently overall and disease-free survival of
patients with colon cancer and is an independent prog-
nostic factor for colon cancer. Moreover, TNM staging
and VEGF expression were also independent negative
prognostic factors on overall survival. Although lymph
node metastasis is commonly considered as an important
prognostic factor for colon cancer, the results in this
study did not show that lymph node metastasis correlate
with overall and disease-free survival, which may be
related to race itself and the relevant regional. Further
investigation of the effects of these factors should be
taken for the reasonable and reliable evidence in the
future.
Recent studies, both in vitro and in vivo, have found the
role of exogenous SPARC on tumor cell biological behav-
iors. For example, in ovarian cancer cells [36], exogenous
exposure to SPARC resulted in the enhanced apoptosis,
whereas endogenous absence of it diminished apoptosis.
In melanoma cells and colorectal cancer cells, exogenous
addition of SPARC significantly inhibited the cell prolifer-
ation and enhanced chemosensitivity of tumor cells that
had become resistant to chemotherapy when compared
with those tumor cells that were deficient in endogenous
SPARC [15].
With the results of current study, we speculate that
endogenous expression of SPARC may inhibit VEGF-
stimulated capacity of angiogenesis in the development
process of colon cancer. The possible reason for the low
expression or absence of SPARC in high malignant colon
cancer tissue is that either endogenous SPARC expression
is down-regulated or its secretion is arrested by other fac-
tors. Based on this hypothesis, insufficient SPARC might
inhibit the production of blood capillary, which leads to
the unlimited growth of tumors.
Conclusions
In summary, the expression of SPARC protein can
emerge in tumor cells and MSC of colon cancer, but
mainly in MSC. SPARC expression in MSC positively
correlates with tumor differentiation and lymph node
metastasis and may be involved in regulation of produc-
tion of angiogenesis factor VEGF. It is believed that inhi-
bition of SPARC expression is associated with the tumor
progress and invasion process of colon cancer. In addi-
tion, low expression or absence of SPARC protein in MSC
can be considered as an important independent unfa-
vourable prognostic factor of colon cancer. Importantly,
the regulatory mechanism points to the possibility that
SPARC-based gene and protein therapy can be used with
current therapeutic modalities to affect tumor regression
in advanced colon cancer refractory to therapy and will
be a meaningful frame of reference of molecular target
therapy of tumor.
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